WO2021022888A9 - 靶向长链非编码rna ddx11-as1的aso、试剂盒及在肝癌治疗中的应用 - Google Patents
靶向长链非编码rna ddx11-as1的aso、试剂盒及在肝癌治疗中的应用 Download PDFInfo
- Publication number
- WO2021022888A9 WO2021022888A9 PCT/CN2020/094281 CN2020094281W WO2021022888A9 WO 2021022888 A9 WO2021022888 A9 WO 2021022888A9 CN 2020094281 W CN2020094281 W CN 2020094281W WO 2021022888 A9 WO2021022888 A9 WO 2021022888A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- liver cancer
- ddx11
- application
- coding rna
- kit
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
提供了一种靶向长链非编码RNA DDX11-AS1的反义寡核苷酸及其在制备用于治疗肝癌的药物中的应用，以及一种肝癌检测试剂盒。该反义寡核苷酸能够通过抑制DDX11-AS1的表达来显著地影响肝癌的发生及发展。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910726294.9 | 2019-08-07 | ||
| CN201910726294.9A CN110452907A (zh) | 2019-08-07 | 2019-08-07 | 靶向长链非编码rna ddx11-as1的aso、试剂盒及在肝癌治疗中的应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2021022888A1 WO2021022888A1 (zh) | 2021-02-11 |
| WO2021022888A9 true WO2021022888A9 (zh) | 2021-04-01 |
Family
ID=68485257
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2020/094281 WO2021022888A1 (zh) | 2019-08-07 | 2020-06-04 | 靶向长链非编码rna ddx11-as1的aso、试剂盒及在肝癌治疗中的应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN110452907A (zh) |
| WO (1) | WO2021022888A1 (zh) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110452907A (zh) * | 2019-08-07 | 2019-11-15 | 浙江大学 | 靶向长链非编码rna ddx11-as1的aso、试剂盒及在肝癌治疗中的应用 |
| CN110804613B (zh) * | 2019-12-09 | 2023-08-15 | 南京苏粤再生医学研究院有限公司 | 一种靶向抑制lncRNA-00861基因表达的siRNA在肝癌治疗中的应用 |
| CN111154872A (zh) * | 2019-12-31 | 2020-05-15 | 浙江大学 | 用于检测肺癌驱动性基因突变的探针及试剂盒 |
| CN113897358B (zh) * | 2021-06-02 | 2023-04-18 | 司达药业（南京）有限公司 | 靶向ensg00000203930基因的反义寡核苷酸及其应用 |
| CN115094140A (zh) * | 2022-06-29 | 2022-09-23 | 山东第一医科大学第一附属医院(山东省千佛山医院) | LncRNA AC026412.3作为肝癌诊断和/或预后标志物的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105779454B (zh) * | 2016-03-23 | 2019-04-09 | 南方医科大学南方医院 | 抑制长链非编码RNA SNHG6表达和肝癌细胞增殖的siRNA-203及应用 |
| CN109718241A (zh) * | 2017-10-31 | 2019-05-07 | 上海市浦东医院（复旦大学附属浦东医院） | 一种肿瘤的基于核酸的靶向治疗方法 |
| CN108546702B (zh) * | 2018-04-10 | 2021-03-12 | 西安交通大学 | 靶向长链非编码RNA DDX11-AS1的siRNA及其在肝癌治疗中的应用 |
| CN109593848B (zh) * | 2018-11-08 | 2020-07-10 | 浙江大学 | 一种肿瘤相关序列、长链非编码rna及其应用 |
| CN109486816B (zh) * | 2018-11-08 | 2021-04-06 | 浙江大学 | 一种用于肿瘤治疗的多聚核苷酸及其应用 |
| CN110452907A (zh) * | 2019-08-07 | 2019-11-15 | 浙江大学 | 靶向长链非编码rna ddx11-as1的aso、试剂盒及在肝癌治疗中的应用 |
-
2019
- 2019-08-07 CN CN201910726294.9A patent/CN110452907A/zh active Pending
-
2020
- 2020-06-04 WO PCT/CN2020/094281 patent/WO2021022888A1/zh active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021022888A1 (zh) | 2021-02-11 |
| CN110452907A (zh) | 2019-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021022888A9 (zh) | 靶向长链非编码rna ddx11-as1的aso、试剂盒及在肝癌治疗中的应用 | |
| BR112019002117A2 (pt) | agente de rnai contra infecção do vírus da hepatite b | |
| ZA202106265B (en) | Compositions and methods for inhibiting gene expression of lpa | |
| WO2018049152A8 (en) | Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
| WO2017027350A3 (en) | Rnai therapy for hepatitis b virus infection | |
| WO2016106400A3 (en) | Rna interference agents for gst-pi gene modulation | |
| WO2008063318A3 (en) | Betulinic acid, derivatives and analogs thereof and uses therefor | |
| EP2426203A3 (en) | Agents useful in treating facioscapulohumeral muscular dystrophy | |
| WO2005112636A3 (en) | COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF PRIMATE POLYOMAVIRUS GENES | |
| MX2021006745A (es) | Constructos de iarn modificados quimicamente y usos de estos. | |
| MX2017014641A (es) | Composiciones y metodos para inhibir la expresion del gen de factor inducible por hipoxia alfa (hif2alfa). | |
| AU2018271862A1 (en) | Combination therapy | |
| WO2018175323A4 (en) | Gemcitabine derivatives for cancer therapy | |
| WO2017087947A3 (en) | Method of treatment of follicular lymphoma with a btk inhibitor | |
| EP4265725A3 (en) | Pharmaceutical composition comprising mirna-3140 for use in treating cancer | |
| EP3978078A4 (en) | COMPLEX, MEDICINE, THERAPEUTIC AGENT FOR CANCER, KIT AND CONJUGATE | |
| AU2018244925A1 (en) | Compositions for the treatment of drug-resistant tumors and methods of use thereof | |
| WO2023178144A3 (en) | Galnac compositions for improving sirna bioavailability | |
| AU2019382824A8 (en) | Method and means to deliver miRNA to target cells | |
| WO2008038267A3 (en) | Use of antisense oligonucleotides against cpla2 in the treatment of cancer | |
| BR112018010736A2 (pt) | oligonucleotídeos antissenso contra il-34 e métodos de uso dos mesmos | |
| WO2019051025A3 (en) | Treatment for aggressive cancers by targeting c9orf72 | |
| WO2023081500A3 (en) | RNAi OLIGONUCLEOTIDE CONJUGATES | |
| WO2018206715A3 (en) | MODIFIED MICROCYSTINS AND NODULARINS | |
| WO2011087343A3 (ko) | Ｈｐｖ 감염과 관련된 암의 치료용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20849969 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20849969 Country of ref document: EP Kind code of ref document: A1 |